Business
Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have agreed to extend their biosimilars alliance to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The effectiveness of the agreement covering tocilizumab is subject to shareholder approval.
About this update from Bio-thera Solutions, Ltd. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the interleukin-6 receptor, indicated for the treatment of multiple inflammatory and autoimmune disorders","length":255,"tagName":"p"}]},{"val":[{"type":"text","content":"Bio-Thera will have responsibility for development, manufacturing, and supply of the biosimilar to Roche's RoActemra® reference brand","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"STADA will have exclusive rights to commercialize the product in the EU, the UK, Switzerland and selected other countries under its own marketing authorization","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":551,"olType":false},{"type":"text","content":"GUANGZHOU, China and BAD VILBEL, Germany, Aug. 22, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have agreed to extend their biosimilars alliance to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The effectiveness of the agreement covering tocilizumab is subject to shareholder approval.","length":567,"tagName":"p"},{"type":"image","alt":"Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab","displaySize":"","headline":null,"caption":"Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":178,"url":"https://media.zenfs.com/en/prnewswire.com/dbb3d33c56b7c7f40a151637db377d46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/efF9idrFj.VSN3LPpbUvcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/dbb3d33c56b7c7f40a151637db377d46","width":400,"height":178}},"href":"https://mma.prnewswire.com/media/2756084/Bio_Thera_Solutions_Ltd___STADA.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Bio-Thera will maintain responsibility for development, manufacturing, and supply of the tocilizumab biosimilar to Roche's RoActemra® reference brand. STADA, including its affiliates,&...